New Biomarkers and Therapeutics Show Potential in Still's Disease
Adult-onset Still’s disease (AOSD) is a rare complex, sporadic, systemic autoinflammatory disease similar to…
View Resource
No Great Options for Treating VEXAS
For patients with the auto-inflammatory disease VEXAS, treatment decisions are unfortunately fraught with tradeoffs…
View Resource
Emapalumab for the treatment of macrophage activation syndrome
Macrophage activation syndrome (MAS) is a term commonly used by rheumatologists to describe a…
View Resource
Rheumatic Associated Macrophage Activation Syndrome
Macrophage Activation Syndrome (MAS) is a hyperinflammatory condition that has a significant mortality risk and…
View Resource
Still’s Disease FAQs
What is the classic ‘triad’ of Still’s disease? Does it affect males and females…
View Resource
ACR 2022 Appraisal, Praise & Critique (11.18.2022)
It was great to be back at an ACR annual meeting, this one in…
View Resource
Here at Last: Treatment Options for VEXAS
We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for…
View Resource
ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory Syndromes
Editor’s note: This article originally appeared March 12, 2024, and is being shared again…
View Resource
Risks associated with mortality in VEXAS
Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS) took the centre stage when it…
View Resource
Myths & Misconceptions with Febrile Disorders
When dealing with a new diagnosis, especially for rare diseases, there may be misconceptions…
View Resource